Hodgkin's lymphoma: 2023 update on treatment

Cancer Biol Med. 2023 Dec 29;21(4):269-273. doi: 10.20892/j.issn.2095-3941.2023.0427.

Authors

Sicong Zhang¹, Xianming Liu¹, Lanfang Li¹, Lihua Qiu¹, Zhengzi Qian¹, Shiyong Zhou¹, Xianhuo Wang¹, Huilai Zhang¹

Affiliation

¹ Department of Lymphoma, Tianjin Medical University Cancer Institute & Hospital, National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, the Sino-US Center for Lymphoma and Leukemia Research, Tianjin 300060, China.

PMID: 38164723
PMCID: PMC11033717
DOI: 10.20892/j.issn.2095-3941.2023.0427

No abstract available

Publication types

Editorial

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Hodgkin Disease* / drug therapy
Hodgkin Disease* / pathology
Hodgkin Disease* / therapy
Humans